Brain autopsy and biomarker studies indicate that the pathology of Alzheimer's disease (AD)
is initiated at least 10–20 years before clinical symptoms. This provides a window of …

Objective To elucidate the relationship between the 2 hallmark proteins of Alzheimer
disease (AD), amyloid-β (Aβ) and tau, and clinical decline over time among cognitively …

Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …

Introduction Plasma markers have been reported to be associated with brain amyloid
burden, tau pathology, or neurodegeneration. We aimed to evaluate whether plasma …

Numerous studies have shown that Alzheimer's Disease (AD) pathology begins before the
onset of clinical symptoms. Because therapies are likely to be more effective if they are …

It is currently unclear whether plasma biomarkers can be used as independent prognostic
tools to predict changes associated with early Alzheimer's disease. In this study, we sought …

Objectives To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to
discriminate early-stage Alzheimer disease (AD)(defined by clinical criteria and …

Objective We investigated the association of plasma amyloid beta (Abeta) 40, Abeta42, and
total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …